Point72 Asset Management
AKRO

Point72 Asset Management’s Akero Therapeutics AKRO Stock Holding History

Point72 Asset Management’s Portfolio AKRO Stock Details AKRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-500,000
Closed -$23.7M – 3877
2025
Q3 		$23.7M Hold
500,000
– – 0.04% 498
2025
Q2 		$26.7M Buy
+500,000
New +$22.7M 0.05% 402

Other funds holding AKRO

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Point72 Asset Management's AKRO Position: Q4 2025 in Review

Point72 Asset Management sold out of Akero Therapeutics (AKRO) in Q4 2025, closing a stake of 1,663,339 shares — an estimated $79M sold.

Point72 Asset Management first reported a position in AKRO in Q2 2019 and held it in 21 quarters. The position peaked at $145M in Q2 2025. 2 funds tracked by Wall St. Rank hold AKRO as of Q4 2025.

  • Point72 Asset Management reported no remaining Akero Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Point72 Asset Management sold 1,663,339 Akero Therapeutics shares in Q4 2025, an estimated $79M.
  • Point72 Asset Management first reported a position in Akero Therapeutics in Q2 2019 and held it in 21 quarters.
  • Point72 Asset Management's Akero Therapeutics position peaked at $145M in Q2 2025.
  • 2 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2025.

Based on Point72 Asset Management's 13F filing for Q4 2025, filed 17 Feb 2026.